{
    "organizations": [],
    "uuid": "4f0bb8b8280b5edc2c27dbd1ebfecb995d94c43a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-apellis-pharmaceuticals-announces/brief-apellis-pharmaceuticals-announces-18-month-results-of-phase-2-study-of-apl-2-in-geographic-atrophy-idUSFWN1QC0VN",
    "ord_in_thread": 0,
    "title": "BRIEF-Apellis Pharmaceuticals Announces 18-Month Results Of Phase 2 Study Of APL-2 In Geographic Atrophy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - Apellis Pharmaceuticals Inc:\n* APELLIS PHARMACEUTICALS ANNOUNCES 18-MONTH RESULTS OF PHASE 2 STUDY (FILLY) OF APL-2 IN GEOGRAPHIC ATROPHY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-22T21:46:00.000+02:00",
    "crawled": "2018-02-23T15:37:01.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "apellis",
        "pharmaceutical",
        "inc",
        "apellis",
        "pharmaceutical",
        "announces",
        "result",
        "phase",
        "study",
        "filly",
        "geographic",
        "atrophy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}